Page 7 - Novartis Oncology Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novartis Scemblix® demonstrates sustained response rate in

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs. Bosulif® .

United statesEast hanoverIsabella zinckJeff legosThomas hungerbuehlerFloriana riccio furnariMichaelj mauroSamir shahParag mahantiJulie masowSloan simpsonAlina levchukNovartis oncology congress hubNovartis oncology communicationsNovartis us external communicationsNovartis external communications

Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
novartis.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from novartis.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalIsabella zinckJeff legosThomas hungerbuehlerCatherine thieblemontSamir shahParag mahantiJulie masowSloan simpsonFiona phillipsAlina levchukAmerican society of clinical oncologyParis universityFollicular lymphoma international prognostic indexNovartis oncology communications

Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

/PRNewswire/ Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix® (asciminib) demonstrating that the results observed in.

United statesEast hanoverMichaelj mauroJeff legosJulie masowSloan simpsonPrnewswire novartisFloriana riccio furnariNovartis oncology congress hubNovartis oncology communicationsNovartis us external communicationsExchange commissionApproval programNj novartis pharmaceuticals corporationAmerican society of hematology annual meeting expositionNovartis pharmaceuticals corp

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

United statesSan antonioNew jerseyEast hanoverIsabella zinckThomas hungerbuehlerAshley bufordSamir shahJulie masowParag mahantiSloan simpsonAlina levchukVirtual scientific programNovartis oncology communicationsNovartis us external communicationsNovartis external communications

Novartis Pharma AG: Novartis data highlight efficacy of Piqray in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

New data underscore efficacy of Piqray, even in those patients with a short treatment duration on prior CDK4/6i or with ESR1 mutations, biomarkers of endocrine resistance1-5 Recent guideline updates

United statesSan antonioNew jerseyEast hanoverIsabella zinckThomas hungerbuehlerAshley bufordSamir shahJulie masowParag mahantiSloan simpsonAlina levchukVirtual scientific programNovartis oncology communicationsNovartis us external communicationsNovartis external communications